Eli Lilly’s diabetes and weight-loss drug Mounjaro debuts in India
Investing.com -- U.S. pharmaceutical company Eli Lilly (NYSE: LLY) has introduced its diabetes and weight-loss drug Mounjaro in India, ahead of its competitor Novo Nordisk (NYSE: NVO ). This comes as India, the world’s most populous country, faces rising levels of obesity and diabetes.
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to ...
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound® As previously ...
A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...
US-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with ...
We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback